Is ibogaine treatment durable? 12-month follow-up of magnesium–ibogaine therapy (MISTIC) in Special Operations Veterans with traumatic brain injuries
Research Square December 17, 2025 Camarin E. Rolle, Nolan Williams, Afik Faerman et al.
A single dose of magnesium-ibogaine produced large and lasting reductions in disability, posttraumatic stress disorder, depression, and anxiety symptoms over 12 months in male U.S. Special Operations Veterans with a history of traumatic brain injury. Of 30 treated participants, 25 completed the full year of follow-up. Effect sizes at 12 months were very large (Cohen's d ≥ 2.18). The estimated probability of sustained remission at one year was 84% for PTSD, 66% for depression, and 61% for anxiety. These results suggest ibogaine may offer durable clinical benefits for TBI-related psychiatric and functional problems, though randomized controlled trials are needed to confirm the findings.